drugset / Trial / NCT06988319

Psilocybin for Chronic Pelvic Pain (CPP) in Women: A Pilot Feasibility Study

NCT06988319

NaSingle-groupOpen-labelTreatment

Summary

The primary aim is to determine the feasibility of enrolling and 15 women with chronic pelvic pain (CPP) that have failed one conventional for CPP to obtain preliminary safety data on a single administration of a moderate dose of pharmaceutical grade psilocybin (25 mg) in combination with psychotherapy sessions (two pre-dose preparatory and three post-dose integration sessions).

Timeline

Start
2026-01-01
Primary completion
2026-12-31
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Psilocybin Other / unclassified 25 mg

Indications